Use of Ketamine in Severe Pain Syndromes

Use of Intravenous Ketamine in Patients with Severe Chronic Pain Syndromes

Ketamine has been shown to have a certain efficiency in chronic pain syndromes. However, it is still not clearly known what is its efficiency and how ketamine is used in real world patients. In this retrospective study, all patients treated with ketamine for chronic pain in our hospital will be reviewed. Patients demographics, pain syndromes as well as outcome criteria will be collected to describe the use of ketamine in pain syndromes.

Study Overview

• Status: Completed
• Conditions: Pain, Chronic; Pain, Intractable; Pain Syndrome; Pain Measurement

Detailed Description

The American Society of Regional Anesthesia and Pain Medicine, together with the American Academy of Pain and the American Society of Anesthesiologists published a consensus guideline in 2018 on the use of ketamine in chronic pain. A review of medical charts of all patients who received ketamine for chronic pain between january 2010 and june 2024 will be done. Demographic data, detailed pain scores, as well as description of the type of pain will be collected. Ketamine usage will be recorded for the dosage, as well as duration of the treatment. Outcome will be measured by before/after pain scores for neuropathic pain, as well as on a visual analog scale. A more global score (good-medium-no effect) will also be collected to get the patient's impression on their treatment. Concomitant pain medication will be collected.

• Study Type: Observational
• Enrollment (Actual): 89

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium, 1070
    • Hopital Universitaire de Bruxelles - Hopital Erasme

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital

Description

Inclusion Criteria:

- All patients who received ketamine as treatment for a pain syndrome during january 2010 until june 2024 at Erasme University Hospital

Exclusion Criteria:

• Age < 18 years
• Patients who expressed their opposition to the use of their medical data
• incomplete medical chart

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient satisfaction	A scale (good-medium-no effect) of the efficacity of ketamine on their pain syndrome	6 month
DN4	Neuropathic pain scale 4	6 month
VAS	Visual analog scale of the pain intensity	6 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concomitant pain medications	Number of concomitant pain medications used by the patient	6 month

Collaborators and Investigators

• Sponsor: Erasme University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2024
• Primary Completion (Actual): February 20, 2025
• Study Completion (Actual): February 20, 2025

Study Registration Dates

• First Submitted: August 1, 2024
• First Submitted That Met QC Criteria: August 1, 2024
• First Posted (Actual): August 5, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 24, 2025
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Mental Disorders; Pathologic Processes; Disease; Somatoform Disorders; Syndrome; Chronic Pain; Pain, Intractable
• Other Study ID Numbers: SRB2024171

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No